Clinical trial
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the…
NCT00038402 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038402 |
|---|---|
| Title | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer |
| Official title | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin |
| Enrollment | 74 |
| Start date | Apr 1, 2001 |
| Primary completion | Nov 1, 2004 |
| Completion | Jul 1, 2011 |
| First posted | May 31, 2002 |
| Last update posted | Jul 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: